# US 2013/0210821 A1 · Methods for Treating Obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0210821 A1
- Document ID: US20130210821A1
- Status: Published application
- Kind: A1
- Application number: 13/700,231
- Filed: 2011-05-27
- Published: 2013-08-15
- Earliest claimed: 2010-05-27
- Inventors: James E. Vath
- Web page: https://patentgrep.com/patent/US20130210821A1

## CPC

- C07D 239/74: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The disclosure provides for methods of treating obesity and related disorders. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.

## Claims

### Claim 1

A method of treating, ameliorating, or controlling obesity in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound represented by:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is H, nitro, halo, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocycloalkyl, NRARA, or SO3RA;
R2 is H, nitro, halo, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocycloalkyl, NRARA, SO3RA, or SRA;
R4 is H, nitro, halo, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocycloalkyl, NRARA, or SO3RA;
R3 is H, C(O)RB, C(O)ORB, C(O)NHRB, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; and
RA, independently for each occurrence, is H or an optionally substituted alkyl; and each RB is independently H, an optionally substituted alkyl, or an optionally substituted aryl.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is represented by:
wherein R1 is H, nitro, halo, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocycloalkyl, NRARA, or SO3RA;
R2 is H, nitro, halo, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocycloalkyl, NRARA, SO3RA, or SRA; each RA is independently H or an optionally, substituted alkyl; and each RB is independently H, an optionally substituted alkyl, or an optionally substituted aryl.

### Claim 3 (depends on 2)

The method of claim 2, wherein R1 is H, nitro, Cl, Br, or SO3H.

### Claim 4 (depends on 2)

The method of claim 2, wherein R2 is H or an optionally substituted alkyl.

### Claim 5 (depends on 4)

The method of claim 4, wherein R2 is methyl which is optionally substituted by one or more of phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl; pyridyl, 1-oxo-pyridyl, furanyl, benzo[1,3]dioxolyl, benzo[1,4]dioxinyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, triazolyl, thiadiazolyl, isoquinolinyl, indazolyl, benzoxazolyl, benzofuryl, indolizinyl, imidazopyridyl, tetrazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, tetrahydroindolyl, azaindolyl, indazolyl, imidazopyridyl, quinazolinyl, purinyl, pyrrolo[2,3]pyrimidinyl, pyrazolo[3,4] pyrimidinyl, benzo(b)thienyl; cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, aziridinyl, oxiranyl, azetidinyl, oxetanyl; piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxo pyrrolidinyl, 4-piperidonyl, tetrahydropyranyl, oxazolidinyl, 2-oxo-oxazolidinyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, morpholinyl, thiomorpholinyl, thiomoφholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolane, tetrahydrofuranyl, or tetrahydrothienyl; each of which may be optionally substituted.

### Claim 6 (depends on 4)

The method of claim 4, wherein R2 is methyl which is optionally substituted by one or more of alkyl, alkenyl, hydroxy, or NRARA.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound is represented by:
wherein
R1 is H, nitro, halo, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocycloalkyl, NRARA, or SO3RA;
R2 is H, nitro, halo, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocycloalkyl, NRARA, SO3RA, or SRA;
R3 is C(O)RB, C(O)ORB, C(O)NHRB, an optionally substituted alkyl, or an optionally substituted alkenyl; each RA is independently H or an optionally substituted alkyl; and each RB is independently H, an optionally substituted alkyl, or an optionally substituted aryl.

### Claim 8 (depends on 7)

The method of claim 7, wherein R1 is H, nitro, Cl, Br, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocycloalkyl, NRARA, or SO3RA.

### Claim 9 (depends on 8)

The method of claim 8, wherein R1 is an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.

### Claim 10 (depends on 9)

The method of claim 9, wherein R1 is optionally substituted by one or more of phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl; pyridyl, 1-oxo-pyridyl, furanyl, benzo[1,3]dioxolyl, benzo[1,4]dioxinyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, triazolyl, thiadiazolyl, isoquinolinyl, indazolyl, benzoxazolyl, benzofuryl, indolizinyl, imidazopyridyl, tetrazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, tetrahydroindolyl, azaindolyl, indazolyl, imidazopyridyl, quinazolinyl, purinyl, pyrrolo[2,3]pyrimidinyl, pyrazolo[3,4] pyrimidinyl, benzo(b)thienyl; cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, aziridinyl, oxiranyl, azetidinyl, oxetanyl; piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxo pyrrolidinyl 4-piperidonyl, tetrahydropyranyl, oxazolidinyl, 2-oxo-oxazolidinyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolane, tetrahydrofuranyl, or tetrahydrothienyl; each of which may be optionally substituted.

### Claim 11 (depends on 7)

The method of claim 7, wherein R2 is H, nitro, Cl, or Br.

### Claim 12 (depends on 7)

The method of claim 7, wherein R3 is C(O)RB, C(O)ORB, C(O)NHRB, an optionally substituted alkyl or an optionally substituted alkenyl.

### Claim 13 (depends on 12)

The method of claim 12, wherein R3 is an optionally substituted ethyl, allyl, or C(O)NHRB, wherein RB is an optionally substituted phenyl or optionally substituted alkyl.

### Claim 14 (depends on 1)

The method of claim 1, wherein the compound is represented by:
wherein
R2 is H, nitro, halo, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocycloalkyl, NRARA, or SO3RA;
R4 is H, nitro, halo, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocycloalkyl, NRARA, or SO3RA;
R3 is H, C(O)RB, C(O)ORB, C(O)NHRB, an optionally substituted alkyl, or an optionally substituted alkenyl; each RA is independently H, or an optionally substituted alkyl; and each RB is independently H, an optionally substituted alkyl, or an optionally substituted aryl.

### Claim 15 (depends on 14)

The method of claim 14, wherein R2 is H or nitro.

### Claim 16 (depends on 14)

The method of claim 14, wherein R4 is H or an optionally substituted alkyl.

### Claim 17 (depends on 14)

The method of claim 14, wherein R3 is H, C(O)RB, C(O)ORB, or an optionally substituted alkyl.

### Claim 18 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable amount does not substantially modulate or suppress angiogenesis.

### Claim 19 (depends on 1)

The method of claim 1, wherein the method comprises orally administering said compound to said subject.

### Claim 20 (depends on 1)

The method of claim 1, wherein the method comprises subcutaneously or intravenously administering said compound to said subject.

### Claim 21 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable amount does not substantially reduce lean body mass of the patient.

### Claim 22 (depends on 1)

The method of claim 1, wherein upon discontinuation of administration of said compound, the patient has durable weight loss maintained for at least about 1 month.

### Claim 23 (depends on 1)

The method of claim 1, wherein the patient is human.

### Claim 24 (depends on 23)

The method of claim 23, wherein the patient has a body mass index greater than or equal to about 25 kg/m2 before the administration.

### Claim 25 (depends on 1)

The method of claim 1, wherein the patient is a companion animal.

### Claim 26 (depends on 1)

The method of claim 1, wherein the patient is a cat or dog.

### Claim 27 (depends on 1)

The method of claim 1, comprising administering said compound in an amount sufficient to establish inhibition of intracellular MetAP2 effective to increase thioredoxin production in the patient and to induce multi organ stimulation of anti-obesity processes in the subject.
